Does CDP-choline modulate phospholipase activities after transient forebrain ischemia?

doi:10.1016/S0006-8993(00)03280-7

Brain Research

Volume 893, Issues 1–2, 2 March 2001, Pages 268-272

https://doi.org/10.1016/S0006-8993(00)03280-7 Get rights and content

Abstract

Ten min forebrain ischemia/1-day reperfusion resulted in significant decreases in total phosphatidylcholine (PtdCho), phosphatidylinositol (PtdIns), and cardiolipin in gerbil hippocampus. CDP-choline restored cardiolipin levels, arachidonic acid content of PtdCho, partially but significantly restored total PtdCho, and had no effect on PtdIns. These data suggest that CDP-choline prevented the activation of phospholipase A₂ (rather than inhibiting phospholipase A₂ activity) but did not affect activities of PtdCho-phospholipases C and/or D, or phosphoinositide-phospholipase C. CDP-choline also provided significant protection for hippocampal CA₁ neurons.

Section snippets

Acknowledgements

This study was supported by start-up funding from University of Wisconsin to AMR.

References (39)

E. Arrigoni et al.
Effects of CDP-choline on phospholipase A₂ and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit
Biochem. Pharmacol.
(1987)
J.M. Clement et al.
CTP: phosphocholine cytidylyltransferase: insights into regulatory mechanisms and novel functions
Biochem. Biophys. Res. Commun.
(1999)
Z. Cui et al.
A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in chinese hamster ovary cells
J. Biol. Chem.
(1996)
A.A. Farooqui et al.
Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders
Chem. Phys. Lipids
(2000)
H. Katsuki et al.
Arachidonic acid as a neurotoxic and neurotrophic substance
Prog. Neurobiol.
(1995)
R. Kumar et al.
Production and effects of platelet-activating factor in the rat brain
Biochim. Biophys. Acta
(1988)
A.M. Rao et al.
Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil
Neurosci. Lett.
(2000)
W.R. Schabitz et al.
The effects of prolonged treatment with citicoline in temporary experimental focal ischemia
J. Neurol. Sci.
(1996)
A. Shuaib et al.
Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase
Exp. Neurol.
(2000)
T. Urabe et al.
Accumulation of 4-hydroxynonenal-modified proteins in hippocampal CA₁ pyramidal neurons precedes delayed neuronal damage in the gerbil brain
Neuroscience
(2000)

J.E. Vance

Eukaryotic lipid-biosynthetic enzymes: the same but not the same

Trends Biochem. Sci.

(1998)

G.B. Weiss

Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline

Life Sci.

(1995)

Y. Yoshihara et al.

Translocation of phospholipase A₂ from cytosol to membranes in rat brain induced by calcium ions

Biochem. Biophys. Res. Commun.

(1990)

M.K. Baskaya et al.

Neuroprotective effects of citicoline on brain edema and blood–brain barrier breakdown after traumatic brain injury

J. Neurosurg.

(2000)

N.G. Bazan

A signal terminator

Nature

(1995)

D.W. Choi

Methods for antagonizing glutamate neurotoxicity

Cerebrovasc. Brain Metab. Rev.

(1990)

K.J. D’Orlando et al.

Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury

Neurol. Res.

(1995)

A.A. Farooqui et al.

Deacylation and reacylation of neural membrane glycerophospholipids — A matter of life and death

J. Mol. Neurosci.

(2000)

A.A. Farooqui et al.

Brain cytosolic phospholipase A₂: localization, role, and involvement in neurological diseases

Neuroscientist

(2000)

Cited by (45)

Additive anxiolytic-like effect of citicoline and ACPA in the non-acute restraint stress (NARS) and acute restraint stress (ARS) mice
2024, Physiology and Behavior
The cannabinoid system plays a key role in stress-related emotional symptoms such as anxiety. Citicoline is a supplemental substance with neuroprotective properties that alleviates anxiety-related behaviors. There is a relation between the actions of cannabinoids and cholinergic systems. So, we decided to evaluate the effects of intracerebroventricular (i.c.v.) infusion of cannabinoid CB1 receptor agents on citicoline-produced response to anxiety-like behaviors in the non-acute restraint stress (NARS) and acute restraint stress (ARS) mice. For i.c.v. microinjection of drugs, a guide cannula was inserted in the left lateral ventricle. ARS was induced by movement restraint for 4 h. Anxiety-related behaviors were assessed using an elevated plus maze (EPM). The results showed that induction of ARS for 4 h decreased the percentage of time spent in the open arms (%OAT) and the percentage of entries to the open arms (%OAE) without affecting locomotor activity, showing anxiogenic-like behaviors. i.c.v. infusion of ACPA (1 µg/mouse) induced an anxiolytic-like effect due to the enhancement of %OAT in the NARS and ARS mice. Nonetheless, i.c.v. microinjection of AM251 (1 µg/mouse) decreased %OAT in the NARS and ARS mice which suggested an anxiogenic-like response. Intraperitoneal (i.p.) administration of citicoline (80 mg/kg) induced an anxiolytic-like effect by the augmentation of %OAT in the ARS mice. Furthermore, when ACPA and citicoline were co-administrated, ACPA potentiated the anxiolytic-like effect induced by citicoline in the NARS and ARS mice. On the other hand, when AM251 and the citicoline were co-injected, AM251 reversed the anxiolytic-like response induced by the citicoline in the NARS and ARS mice. The results of this research exhibited an additive effect between citicoline and ACPA on the induction of anxiolytic-like response in the NARS and ARS mice. Our results indicated an interaction between citicoline and cannabinoid CB1 receptor drugs on the control of anxiety-like behaviors in the NARS and ARS mice.
Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: An isobologram analysis
2020, Brain Research
Citation Excerpt :
So, citicoline potentiated the anxiolytic response produced by morphine-sensitization. In the current study, we used citicoline which has been revealed to be a supplemental drug with neuroprotective effects that enhances the level of some neurotransmitters, for example, acetylcholine, dopamine, norepinephrine, and serotonin, which improve management of various disorders and neurodegenerative diseases (Adibhatla and Hatcher, 2005; Alvarez-Sabin and Roman, 2013; Brown et al., 2007; Rao et al., 2001). Based on some of the studies, the application of citicoline induced antidepressant, anticonvulsant and antianxiety effects (Abdolmaleki et al., 2016; Roohi-Azizi et al., 2018).
In the present study, the effects of intraperitoneal (i.p.) injections of citalopram and citicoline on morphine-induced anxiolytic effects were investigated in non-sensitized and morphine-sensitized mice using elevated plus-maze (EPM). Subcutaneous (s.c.) administration morphine (5 mg/kg) increased the percentage of open arm time (%OAT, in morphine-sensitized mice), and open arm entries (%OAE, in non-sensitized mice), but not a locomotor activity, indicating an anxiolytic response to morphine. On the other hand, i.p. administration of naloxone decreased %OAT (morphine-sensitized mice), and %OAE (non-sensitized and morphine-sensitized mice), but not a locomotor activity, showing an anxiogenic effect to naloxone. Moreover, i.p.co-administration of citalopram (5 and 10 mg/kg) and citicoline (75 mg/kg) induced the anxiolytic effect. Interestingly, i.p. co-administration of low doses of citalopram (0.5, 1 and 2.5 mg/kg) and citicoline (25 mg/kg) significantly increased %OAT and %OAE in non-sensitized as well as %OAT in morphine-sensitized mice, indicating an anxiolytic effect. An isobolographic analysis of data was performed, presenting a synergistic interaction between citalopram and citicoline upon the production of anxiolytic effect in non-sensitized and morphine-sensitized mice. In conclusion, it seems that (1) morphine sensitization affects the anxiety behavior in the EPM, (2) μ-opioid receptors play an important role in morphine anxiolytic effect, (3) citalopram and citicoline induced anti-anxiety effect, (4) a synergistic effect of citalopram and citicoline upon induction of anti-anxiety behavior in non-sensitized and morphine-sensitized mice.
Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice
2018, Physiology and Behavior
Citation Excerpt :
Moreover, citicoline is an effective agent in therapy of amphetamine and cocaine dependency and mood disorders [17–19]. The key neuroprotective role of citicoline may be related to neuronal membrane phospholipids synthesis and various neurotransmitter levels such as acetylcholine, dopamine, and norepinephrine [18, 20–22]. It seems, citicoline has antidepressant effect as an adjuvant drug in unipolar and bipolar depression by increasing monoaminergic neurotransmitters [23, 24].
Depression is associated with significant functional disabilities. Application of new drugs which could enhance the effectiveness of antidepressants drug and reduce side effects of their long-term use seems necessary. Citicoline is used as an effective chemical agent for improving the symptoms of some neurodegenerative diseases. Therefore, in this survey, the application of citicoline as an adjuvant drug was evaluated in mice model of depression. A total of 180 adult NMRI male albino mice were used in this study. All groups were exposed to chronic unexpected mild stress (CUMS) followed by treatment with various doses of citalopram or/and citicoline or saline for 21 days. Sucrose preference (SP), open field (OF), and forced swimming test (FST) were applied to evaluate depression symptoms in the groups. The results indicated that only citicoline at the 5 mg/kg dose had shifted its status from being noneffective to become significantly effective in the co-administered group. The means of SP, OFT, and FST of the treatment groups were significantly different in favor of co-administered group compared with the other groups as well as the control group. Based on the results, it can be concluded that administration of citicoline, as an adjuvant drug, in combination with citalopram, enhanced the effectiveness of selective serotonin reuptake inhibitors (SSRI) drugs for depression treatment.
Protecting the retinal neurons from glaucoma: Lowering ocular pressure is not enough
2012, Pharmacological Research
Citation Excerpt :
Indeed, citicoline has been shown to increase, in the brain, the formation of phosphatidylcholine and other phospholipids both in vitro and in vivo studies [165,166]. Moreover, citicoline is also able to abolish PLA2 activation following brain injury [167], hence preventing post-insult PLA2 stimulation may represent an important mechanism of neuroprotection provided by citicoline [168]. The rescue of RGCs from apoptosis may represent, as previously underscored, a critical step to improve neurodegeneration in glaucoma.
The retina is theater of a number of biochemical reactions allowing, within its layers, the conversion of light impulses into electrical signals. The axons of the last neuronal elements, the ganglion cells, form the optic nerve and transfer the signals to the brain. Therefore, an appropriate cellular communication, not only within the different retinal cells, but also between the retina itself and the other brain structures, is fundamental. One of the most diffuse pathologies affecting retinal function and communication, which thus reverberates in the whole visual system, is glaucoma. This insidious disease is characterized by a progressive optic nerve degeneration and sight loss which may finally lead to irreversible blindness. Nevertheless, the progressive nature of this pathology offers an opportunity for therapeutic intervention. To better understand the cellular processes implicated in the development of glaucoma useful to envision a targeted pharmacological strategy, this manuscript first examines the complex cellular and functional organization of the retina and subsequently identifies the targets sensitive to neurodegeneration. Within this context, high ocular pressure represents a key risk factor. However, recent literature findings highlight the concept that lowering ocular pressure is not enough to prevent/slow down glaucomatous damage, suggesting the importance of combining the hypotensive treatment with other pharmacological approaches, such as the use of neuroprotectants. Therefore, this important and more novel aspect is extensively considered in this review, also emphasizing the idea that the neuroprotective strategy should be extended to the entire visual system and not restricted to the retina.
Citicoline in the Treatment of Mild Cognitive Impairment in Blood Relatives of Patients with Alzheimer’s Disease: Immediate and Long-Term Effects of Course Therapy
2021, Psychiatry (Moscow)
Crystallization Process Control and Crystal Size Distribution of the Citicoline Sodium
2020, Chinese Journal of Pharmaceutical Biotechnology

View all citing articles on Scopus

View full text

Short communicationDoes CDP-choline modulate phospholipase activities after transient forebrain ischemia?

Abstract

Section snippets

Acknowledgements

Biochem. Pharmacol.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Chem. Phys. Lipids

Prog. Neurobiol.

Biochim. Biophys. Acta

Neurosci. Lett.

J. Neurol. Sci.

Exp. Neurol.

Neuroscience

Trends Biochem. Sci.

Life Sci.

Biochem. Biophys. Res. Commun.

Neuroprotective effects of citicoline on brain edema and blood–brain barrier breakdown after traumatic brain injury

J. Neurosurg.

A signal terminator

Nature

Methods for antagonizing glutamate neurotoxicity

Cerebrovasc. Brain Metab. Rev.

Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury

Neurol. Res.

Deacylation and reacylation of neural membrane glycerophospholipids — A matter of life and death

J. Mol. Neurosci.

Brain cytosolic phospholipase A2: localization, role, and involvement in neurological diseases

Neuroscientist

Short communication
Does CDP-choline modulate phospholipase activities after transient forebrain ischemia?

Brain cytosolic phospholipase A₂: localization, role, and involvement in neurological diseases